Capital Impact Advisors LLC Reduces Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Capital Impact Advisors LLC trimmed its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 52.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,965 shares of the biotechnology company’s stock after selling 34,534 shares during the quarter. Capital Impact Advisors LLC’s holdings in Exelixis were worth $601,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in shares of Exelixis by 4.9% in the first quarter. BlackRock Inc. now owns 36,214,174 shares of the biotechnology company’s stock worth $702,917,000 after buying an additional 1,683,880 shares during the last quarter. Vanguard Group Inc. raised its holdings in Exelixis by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 31,284,832 shares of the biotechnology company’s stock worth $490,546,000 after purchasing an additional 220,099 shares during the period. Farallon Capital Management LLC raised its holdings in Exelixis by 115.9% in the 1st quarter. Farallon Capital Management LLC now owns 23,466,000 shares of the biotechnology company’s stock worth $455,475,000 after purchasing an additional 12,597,851 shares during the period. Renaissance Technologies LLC raised its holdings in Exelixis by 2.1% in the 1st quarter. Renaissance Technologies LLC now owns 15,279,389 shares of the biotechnology company’s stock worth $296,573,000 after purchasing an additional 318,300 shares during the period. Finally, State Street Corp raised its holdings in Exelixis by 3.4% in the 3rd quarter. State Street Corp now owns 13,019,900 shares of the biotechnology company’s stock worth $204,152,000 after purchasing an additional 423,520 shares during the period. 93.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on EXEL shares. Leerink Partnrs reissued a “market perform” rating on shares of Exelixis in a report on Tuesday, August 8th. Oppenheimer increased their target price on Exelixis from $25.00 to $29.00 and gave the company an “outperform” rating in a report on Tuesday, August 22nd. Barclays reduced their target price on Exelixis from $25.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, August 3rd. SVB Leerink started coverage on Exelixis in a report on Tuesday, August 8th. They set a “market perform” rating and a $18.00 target price for the company. Finally, Morgan Stanley increased their target price on Exelixis from $21.00 to $22.00 and gave the company an “equal weight” rating in a report on Wednesday, August 2nd. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $24.73.

Exelixis Trading Up 0.3 %

Exelixis stock traded up $0.07 during mid-day trading on Wednesday, hitting $22.16. The company’s stock had a trading volume of 222,471 shares, compared to its average volume of 2,714,894. The firm has a market capitalization of $7.06 billion, a PE ratio of 43.31, a price-to-earnings-growth ratio of 1.51 and a beta of 0.67. Exelixis, Inc. has a 1 year low of $14.87 and a 1 year high of $22.80. The stock’s fifty day moving average is $20.76 and its two-hundred day moving average is $19.53.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.10. The company had revenue of $469.85 million during the quarter, compared to analyst estimates of $448.59 million. Exelixis had a return on equity of 6.53% and a net margin of 9.58%. On average, equities analysts expect that Exelixis, Inc. will post 0.71 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Christopher J. Senner sold 60,000 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $20.51, for a total transaction of $1,230,600.00. Following the completion of the transaction, the chief financial officer now directly owns 571,631 shares in the company, valued at $11,724,151.81. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, EVP Patrick J. Haley sold 30,553 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $20.67, for a total transaction of $631,530.51. Following the completion of the transaction, the executive vice president now directly owns 285,467 shares in the company, valued at $5,900,602.89. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Christopher J. Senner sold 60,000 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $20.51, for a total value of $1,230,600.00. Following the transaction, the chief financial officer now owns 571,631 shares of the company’s stock, valued at $11,724,151.81. The disclosure for this sale can be found here. Over the last three months, insiders sold 150,863 shares of company stock worth $3,059,080. Company insiders own 2.90% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.